CD44 and breast carcinoma: However, the results have shown that cisplatin more specifically targeted progenitor cells, rather than the stem breast cancer cells, with the reduction of the population of CD24−/CD44+ and ALDH1A1 MDA-MB-231 cells being at higher folds in tpMDA, compared to tsMDA (Figure 2).